- Template for reporting results of biomarker testing of specimens from patients with gastrointestinal stromal tumors. Archives of Pathology and Laboratory Medicine. 2015 Academic Article GET IT
Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
Annals of Surgery.
Times cited: 67
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
New England Journal of Medicine.
Times cited: 3142